Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS

Blood

Volumn 125, Issue 21, 2015, Pages 3253-3262

  Cofiell, Roxanne ^a   Kukreja, Anjli ^a   Bedard, Krystin ^a   Yan, Yan ^a   Mickle, Angela P ^a   Ogawa, Masayo ^a   Bedrosian, Camille L ^a   Faas, Susan J ^a  

^a ALEXION PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BINDING PROTEIN; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; CLUSTERIN; COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYSTATIN C; D DIMER; ECULIZUMAB; HAPTOGLOBIN; LACTATE DEHYDROGENASE; PROTHROMBIN; THROMBOMODULIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR RECEPTOR 1; VASCULAR CELL ADHESION MOLECULE 1; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE INCREASE; ENDOTHELIUM LESION; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; INFLAMMATION; KIDNEY INJURY; MALE; MULTICENTER STUDY; MUTATION; OPEN STUDY; PLASMA EXCHANGE; PLASMA TRANSFUSION; PRIORITY JOURNAL; RISK; THROMBOCYTE COUNT; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; ACUTE KIDNEY INJURY; ATYPICAL HEMOLYTIC UREMIC SYNDROME; BLOOD; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; VASCULAR ENDOTHELIUM;

ACUTE KIDNEY INJURY; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; BIOMARKERS; COMPLEMENT ACTIVATION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INFLAMMATION; MALE; THROMBOSIS;

EID: 84936978963     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-09-600411     Document Type: Article

References (86)

1. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(17): 1676-1687.
2. Licht C, Pluthero FG, Li L, et al. Plateletassociated complement factor H in healthy persons and patients with atypical HUS. Blood. 2009;114(20):4538-4545.
3. Lemaire M, Frémeaux-Bacchi V, Schaefer F, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet. 2013; 45(5):531-536.
4. Bu F, Maga T, Meyer NC, et al. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2014;25(1):55-64.
5. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10): 1844-1859.
6. Zipfel PF, Heinen S, Skerka C. Thrombotic microangiopathies: new insights and new challenges. Curr Opin Nephrol Hypertens. 2010; 19(4):372-378.
7. Waters AM, Licht C. aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol. 2011;26(1): 41-57.
8. Cataland SR, Wu HM. How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome. Blood. 2014;123(16): 2478-2484.
9. Weitz IC. Complement the hemostatic system: an intimate relationship. Thromb Res. 2014; 133(Suppl 2):S117-S121.
10. Ritis K, Doumas M, Mastellos D, et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol. 2006;177(7):4794-4802.
11. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol. 2012; 8(11):622-633.
12. Couser WG. Complement inhibitors and glomerulonephritis: are we there yet? J Am Soc Nephrol. 2003;14(3):815-818.
13. Hindmarsh EJ, Marks RM. Complement activation occurs on subendothelial extracellular matrix in vitro and is initiated by retraction or removal of overlying endothelial cells. J Immunol. 1998; 160(12):6128-6136.
14. Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121(25):4985-4996, quiz 5105.
15. Noris M, Bresin E, Mele C, Remuzzi G, Caprioli J. Atypical hemolytic-uremic syndrome. In: Pagon RA, Adam NP, Ardinger HH, et al, eds. GeneReviews. Seattle, WA: University of Washington; 1993.
16. Campistol JM, Arias M, Ariceta G, et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia. 2013;33(1):27-45.
17. Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011;6: 60.
18. Hirt-Minkowski P, Dickenmann M, Schifferli JA. Atypical hemolytic uremic syndrome: update on the complement system and what is new. Nephron Clin Pract. 2010;114(4):c219-c235.
19. Laurence J. Atypical hemolytic uremic syndrome (aHUS): making the diagnosis. Clin Adv Hematol Oncol. 2012;10(10 Suppl 17):1-12.
20. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V; French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8(11): 643-657.
21. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013; 368(23):2169-2181.
22. US Food and Drug Administration. Soliris (eculizumab). Cheshire, CT: Alexion Pharmaceuticals, Inc. Available at: http://soliris. net/sites/default/files/assets/soliris-pi.pdf. Accessed April 10, 2015.
23. European Medicines Agency. Soliris (eculizumab). Paris, France: Alexion Europe SAS. Available at: http://www.ema.europa.eu/docs/ en-GB/document-library/EPAR-Summary- for-the-public/human/000791/WC500054210.pdf. Accessed April 10, 2015.
24. Fakhouri F, Hourmant M, Campistol JM, et al. Eculizumab (ECU) inhibits thrombotic microangiopathy (TMA) and improves renal function in adult atypical hemolytic uremic syndrome (aHUS) patients (Pts) [abstract]. J Am Soc Nephrol. 2013;24:49A-50A. Abstract FR-OR057.
25. Fakhouri F, Hourmant M, Campistol JM, et al. Eculizumab inhibits thrombotic microangiopathy (TMA) and improves hematologic parameters and renal function in adults patients (Pts) with atypical hemolytic uremic syndrome (aHUS). Presented at: Annual Congress of the American Society of Nephrology; November 8, 2013; Atlanta, GA.
26. Pryzdial ELG, Isenman DE. Alternative complement pathway activation fragment Ba binds to C3b. Evidence that formation of the factor B-C3b complex involves two discrete points of contact. J Biol Chem. 1987;262(4):1519-1525.
27. Niewczas MA, Ficociello LH, Johnson AC, et al. Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol. 2009;4(1):62-70.
28. Okusawa S, Yancey KB, van der Meer JW, et al. C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha. J Exp Med. 1988;168(1): 443-448.
29. Yan J, Nunn AD, Thomas R. Selective induction of cell adhesion molecules by proinflammatory mediators in human cardiac microvascular endothelial cells in culture. Int J Clin Exp Med. 2010;3(4):315-331.
30. Tedesco F, Pausa M, Nardon E, Introna M, Mantovani A, Dobrina A. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med. 1997;185(9):1619-1627.
31. Blann AD, Seigneur M, Steiner M, Boisseau MR, McCollum CN. Circulating endothelial cell markers in peripheral vascular disease: relationship to the location and extent of atherosclerotic disease. Eur J Clin Invest. 1997; 27(11):916-921.
32. Boehme MW, Deng Y, Raeth U, et al. Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: in vivo and in vitro studies. Immunology. 1996;87(1): 134-140.
33. Weitz IC, Razavi P, Rochanda L, et al. Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation. Thromb Res. 2012;130(3):361-368.
34. Ballermann BJ. Endothelial cell activation. Kidney Int. 1998;53(6):1810-1826.
35. Acosta J, Qin X, Halperin J. Complement and complement regulatory proteins as potential molecular targets for vascular diseases. Curr Pharm Des. 2004;10(2):203-211.
36. Aronson DL, Stevan L, Ball AP, Franza BR Jr, Finlayson JS. Generation of the combined prothrombin activation peptide (F1-2) during the clotting of blood and plasma. J Clin Invest. 1977; 60(6):1410-1418.
37. Graeff H, Hafter R. Detection and relevance of crosslinked fibrin derivatives in blood. Semin Thromb Hemost. 1982;8(1):57-68.
38. Dieterle F, Perentes E, Cordier A, et al. Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nat Biotechnol. 2010;28(5):463-469.
39. Kamijo A, Kimura K, Sugaya T, et al. Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med. 2004;143(1):23-30.
40. Sanders JS, Huitema MG, Hanemaaijer R, van Goor H, Kallenberg CG, Stegeman CA. Urinary matrix metalloproteinases reflect renal damage in anti-neutrophil cytoplasm autoantibodyassociated vasculitis. Am J Physiol Renal Physiol. 2007;293(6):F1927-F1934.
41. Albrecht EA, Chinnaiyan AM, Varambally S, et al. C5a-induced gene expression in human umbilical vein endothelial cells. Am J Pathol. 2004;164(3): 849-859.
42. Girardi G, Mackman N. Tissue factor in antiphospholipid antibody-induced pregnancy loss: a pro-inflammatory molecule. Lupus. 2008; 17(10):931-936.
43. Nangaku M, Shankland SJ, Couser WG, Johnson RJ. A new model of renal microvascular injury. Curr Opin Nephrol Hypertens. 1998;7(4):457-462.
44. Zhou W, Farrar CA, Abe K, et al. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest. 2000;105(10):1363-1371.
45. Hattori R, Hamilton KK, McEver RP, Sims PJ. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem. 1989;264(15):9053-9060.
46. Saadi S, Holzknecht RA, Patte CP, Stern DM, Platt JL. Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med. 1995;182(6):1807-1814.
47. Iglesias J, Marik PE, Levine JS; Norasept II Study Investigators. Elevated serum levels of the type I and type II receptors for tumor necrosis factoralpha as predictive factors for ARF in patients with septic shock. Am J Kidney Dis. 2003;41(1):62-75.
48. Brockhaus M, Bar-Khayim Y, Gurwicz S, Frensdorff A, Haran N. Plasma tumor necrosis factor soluble receptors in chronic renal failure. Kidney Int. 1992;42(3):663-667.
49. Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214(2):149-160.
50. Hamilton KK, Hattori R, Esmon CT, Sims PJ. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem. 1990;265(7):3809-3814.
51. Levy O, Jean-Jacques RM, Cywes C, et al. Critical role of the complement system in group B streptococcus-induced tumor necrosis factor alpha release. Infect Immun. 2003;71(11): 6344-6353.
52. Ding BS, Hong N, Christofidou-Solomidou M, et al. Anchoring fusion thrombomodulin to the endothelial lumen protects against injury-induced lung thrombosis and inflammation. Am J Respir Crit Care Med. 2009;180(3):247-256.
53. Herget-Rosenthal S, Poppen D, Hüsing J, et al. Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clin Chem. 2004;50(3):552-558.
54. Herget-Rosenthal S, van Wijk JA, Bröcker-Preuss M, Bökenkamp A. Increased urinary cystatin C reflects structural and functional renal tubular impairment independent of glomerular filtration rate. Clin Biochem. 2007;40(13-14):946-951.
55. Hall IE, Koyner JL, Doshi MD, Marcus RJ, Parikh CR. Urine cystatin C as a biomarker of proximal tubular function immediately after kidney transplantation. Am J Nephrol. 2011;33(5): 407-413.
56. Musiał K, Zwoliñska D. Matrix metalloproteinases (MMP-2,9) and their tissue inhibitors (TIMP-1,2) as novel markers of stress response and atherogenesis in children with chronic kidney disease (CKD) on conservative treatment. Cell Stress Chaperones. 2011;16(1):97-103.
57. Kamijo A, Sugaya T, Hikawa A, et al. Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: a multicenter trial. J Lab Clin Med. 2005;145(3): 125-133.
58. Väkevä A, Meri S, Lehto T, Laurila P. Activation of the terminal complement cascade in renal infarction. Kidney Int. 1995;47(3):918-926.
59. Hidaka S, Kränzlin B, Gretz N, Witzgall R. Urinary clusterin levels in the rat correlate with the severity of tubular damage and may help to differentiate between glomerular and tubular injuries. Cell Tissue Res. 2002;310(3):289-296.
60. Metzger J, Kirsch T, Schiffer E, et al. Urinary excretion of twenty peptides forms an early and accurate diagnostic pattern of acute kidney injury. Kidney Int. 2010;78(12):1252-1262.
61. Del Conde I, Crúz MA, Zhang H, López JA, Afshar-Kharghan V. Platelet activation leads to activation and propagation of the complement system. J Exp Med. 2005;201(6):871-879.
62. Montinaro V, Lopez A, Monno R, et al. Renal C3 synthesis in idiopathic membranous nephropathy: correlation to urinary C5b-9 excretion. Kidney Int. 2000;57(1):137-146.
63. Ogrodowski JL, Hebert LA, Sedmak D, Cosio FG, Tamerius J, Kolb W. Measurement of SC5b-9 in urine in patients with the nephrotic syndrome. Kidney Int. 1991;40(6):1141-1147.
64. Burwick RM, Burwick NR, Feinberg BB. Eculizumab fails to inhibit generation of C5a in vivo. Blood. 2014;124(23):3502-3503.
65. Bonventre JV, Zuk A. Ischemic acute renal failure: an inflammatory disease? Kidney Int. 2004;66(2): 480-485.
66. Friedewald JJ, Rabb H. Inflammatory cells in ischemic acute renal failure. Kidney Int. 2004; 66(2):486-491.
67. Noronha IL, Fujihara CK, Zatz R. The inflammatory component in progressive renal disease-are interventions possible? Nephrol Dial Transplant. 2002;17(3):363-368.
68. Cole DS, Morgan BP. Beyond lysis: how complement influences cell fate. Clin Sci (Lond). 2003;104(5):455-466.
69. Tsuji S, Kaji K, Nagasawa S. Activation of the alternative pathway of human complement by apoptotic human umbilical vein endothelial cells. J Biochem. 1994;116(4):794-800.
70. Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554-562.
71. Nevard CH, Jurd KM, Lane DA, Philippou H, Haycock GB, Hunt BJ. Activation of coagulation and fibrinolysis in childhood diarrhoea-associated haemolytic uraemic syndrome. Thromb Haemost. 1997;78(6):1450-1455.
72. Chandler WL, Jelacic S, Boster DR, et al. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med. 2002;346(1):23-32.
73. Hillmen P, Muus P, Dührsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110(12): 4123-4128.
74. Cataland SR, Holers VM, Geyer S, Yang S, Wu HM. Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood. 2014; 123(24):3733-3738.
75. Jodele S, Fukuda T, Vinks A, et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant. 2014;20(4):518-525.
76. Peffault de Latour R, Fremeaux-Bacchi V, Porcher R, et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood. 2015;125(5):775-783.
77. Cugno M, Gualtierotti R, Possenti I, et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost. 2014;12(9):1440-1448.
78. Noris M, Galbusera M, Gastoldi S, et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood. 2014; 124(11):1715-1726.
79. Chatelet V, Frémeaux-Bacchi V, Lobbedez T, Ficheux M, Hurault de Ligny B. Safety and longterm efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant. 2009;9(11): 2644-2645.
80. Carr R, Cataland SR. Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation. Ann Hematol. 2013;92(6):845-846.
81. Alachkar N, Bagnasco SM, Montgomery RA. Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft. Transpl Int. 2012;25(8):e93-e95.
82. Cayci FS, Cakar N, Hancer VS, Uncu N, Acar B, Gur G. Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation. Pediatr Nephrol. 2012;27(12):2327-2331.
83. Pu JJ, Sido A. Successful discontinuation of eculizumab therapy in a patient with aHUS. Ann Hematol. 2014;93(8):1423-1425.
84. Gulleroglu K, Fidan K, Hançer VS, Bayrakci U, Baskin E, Soylemezoglu O. Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab. Pediatr Nephrol. 2013;28(5): 827-830.
85. Ardissino G, Testa S, Possenti I, et al. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis. 2014; 64(4):633-637.
86. Ståhl AL, Vaziri-Sani F, Heinen S, et al. Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood. 2008;111(11):5307-5315.